Clinical Trial Update: A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) [Phase 2]

View source ↗

Summary

This clinical trial update reports completion of a Phase 2 study evaluating three dose levels of JNJ-31001074 for adults with Attention-Deficit/Hyperactivity Di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• JNJ-31001074

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Attention Deficit Hyperactivity Disorder | Phase 2 | Status: COMPLETED